Trials / Completed
CompletedNCT01334996
Use of Tamoxifen in Systemic Mastocytosis
Treatment of Systemic Mastocytosis With Tamoxifen
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1 (actual)
- Sponsor
- Mayo Clinic · Academic / Other
- Sex
- All
- Age
- 21 Years
- Healthy volunteers
- Not accepted
Summary
In this study, the investigators will determine the utility of Tamoxifen, a non-cytotoxic agent, to improve quality of life, biochemical parameters, and bone marrow involvement in systemic mastocytosis patients having 1) up to 40% bone marrow infiltration by mast cells and/or 2) mediator-release symptoms which are not controlled by tolerated doses of standard "non-cytotoxic" medications regardless of the percentage bone marrow involvement by mastocytosis. The dose of Tamoxifen will be 40 mg/day and the duration of treatment will be for one year. Patients currently taking interferon alfa, imatinib mesylate, or cladribine will be excluded until these medications have been stopped.
Detailed description
Not desired
Conditions
Timeline
- Start date
- 2005-02-01
- Primary completion
- 2019-08-28
- Completion
- 2019-08-28
- First posted
- 2011-04-13
- Last updated
- 2020-04-10
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01334996. Inclusion in this directory is not an endorsement.